E-LIB Suche - Ergebnisse für: van der Ryst, Elna

1

Clinical Presentation, Treatment Response, and Virology Out..:

Steytler, John ; van der Ryst, Elna ; Craig, Charles...
Clinical Infectious Diseases. 76 (2022) 3 - p. 389-397 , 2022

Link: https://doi.org/10.1093/..

2

Characterization of Viruses in Phase 3 and Phase 3b Trials ..:

Steytler, John ; Craig, Charles ; van der Ryst, Elna...
Clinical Infectious Diseases. 76 (2022) 6 - p. 996-1002 , 2022

Link: https://doi.org/10.1093/..

3

Safety, adherence, and HIV-1 seroconversion among women usi..:

Nel, Annalene ; van Niekerk, Neliëtte ; Van Baelen, Ben...
The Lancet HIV. 8 (2021) 2 - p. e77-e86 , 2021

Link: https://doi.org/10.1016/..

4

Incidence of CXCR4 tropism and CCR5-tropic resistance in tr..:

Jubb, Becky ; Lewis, Marilyn ; McFadyen, Lynn...
Antiviral Chemistry and Chemotherapy. 27 (2019) - p. 204020661989570 , 2019

Link: https://doi.org/10.1177/..

5

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treat..:

Giaquinto, Carlo ; Mawela, Muthuhadini Patience ; Chokephaibulkit, Kulkanya...
Pediatric Infectious Disease Journal. 37 (2018) 5 - p. 459-465 , 2018

Link: https://doi.org/10.1097/..

6

Clonal analysis of HIV-1 genotype and function associated w..:

Lewis, Marilyn ; Mori, Julie ; Toma, Jonathan...
PLOS ONE. 13 (2018) 12 - p. e0204099 , 2018

Link: https://doi.org/10.1371/..

7

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 In..:

Van Der Ryst, Elna
Frontiers in Immunology. 6 (2015) - p. , 2015

Link: https://doi.org/10.3389/..

8

Development of maraviroc, a CCR5 antagonist for treatment o..:

van der Ryst, Elna ; Heera, Jayvant ; Demarest, James.
Annals of the New York Academy of Sciences. 1346 (2015) 1 - p. 7-17 , 2015

Link: https://doi.org/10.1111/..

9

An exploratory survey measuring stigma and discrimination e..:

dos Santos, Monika ML ; Kruger, Pieter ; Mellors, Shaun E..
BMC Public Health. 14 (2014) 1 - p. , 2014

Link: https://doi.org/10.1186/..

10

Discovery and Development of Maraviroc, a CCR5 Antagonist f..:

, In: Case Studies in Modern Drug Discovery and Development,

Dorr, Patrick ; Stammen, Blanda ; van der Ryst, Elna - p. 196-226 , 2012

Link: https://doi.org/10.1002/..

11

Maraviroc versus Efavirenz, Both in Combination with Zidovu..:

Cooper, David A. ; Heera, Jayvant ; Goodrich, James...
The Journal of Infectious Diseases. 201 (2010) 6 - p. 803-813 , 2010

Link: https://www.jstor.org/st..

12

CCR5 Antagonists: Host-Targeted Antiviral Agents for the Tr..:

Westby, Mike ; Ryst, Elna van der
Antiviral Chemistry and Chemotherapy. 20 (2010) 5 - p. 179-192 , 2010

Link: https://doi.org/10.3851/..

13

Baseline CD4+T-cell counts and weighted background suscepti..:

Schapiro, Jonathan M ; Boucher, Charles AB ; Kuritzkes, Daniel R...
Antiviral Therapy. 16 (2010) 3 - p. 395-404 , 2010

Link: https://doi.org/10.3851/..

14

Maraviroc versus Efavirenz, Both in Combination with Zidovu..:

Cooper, David A. ; Heera, Jayvant ; Goodrich, James...
The Journal of Infectious Diseases. 201 (2010) 6 - p. 803-813 , 2010

Link: https://doi.org/10.1086/..

15

A Double‐Blind, Placebo‐Controlled Trial of Maraviroc in Tr..:

Saag, Michael ; Goodrich, James ; Fätkenheuer, Gerd...
The Journal of Infectious Diseases. 199 (2009) 11 - p. 1638-1647 , 2009

Link: https://doi.org/10.1086/..